The CamPROBE® device is now available to more healthcare providers across the UK. The device makes collecting biopsies for prostate cancer safer and more comfortable.
CamPROBE (Cambridge Prostate Biopsy Device) was developed by Professor Vincent Gnanapragasam and his team at Addenbrooke’s Hospital and the University of Cambridge.
The device reduces the risk of infection and can distribute local anaesthetic during the procedure meaning it is less painful than other methods. At the same time, it provides access to collect and test samples from all areas of the prostate.
More than 85 per cent of patients said they would recommend the CamPROBE procedure to someone else having a prostate biopsy.
Prof Vincent Gnanapragasam, urology consultant at Cambridge University Hospitals NHS Foundation Trust
The simple, cost-effective design and ergonomic functionality represent a step-change in prostate biopsies, with the potential to set a new standard of care.
Prostate cancer is the most common cancer in men in the UK, with over 55,000 cases diagnosed each year. Early detection through accurate and accessible sampling and diagnostics is critical to ensure more men get treatment sooner.
CamPROBE is now more widely available in the UK thanks to a partnership between group companies Medovate and J.E.B. Technologies – that are responsible for commercialising CamPROBE – and a newly appointed UK distributor Aquilant.
The project was supported by Cambridge Enterprise, the University’s innovation arm, and Health Tech Enterprise, which provided commercialisation and IP expertise. A grant from the National Institute for Health and Care Research (NIHR) supported the clinical development and evaluation of the device, which has also been supported by funding from Addenbrooke's Charitable Trust.
